Verve Therapeutics Advances Gene Editing with Eli Lilly Deal

Introduction

Verve Therapeutics Inc (NASDAQ: VERV) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. Founded in 2018, Verve is developing single-course in vivo gene editing medicines targeting atherosclerotic cardiovascular disease (ASCVD). Its lead programs focus on the PCSK9, ANGPTL3, and LPA genes, which have been supported by human genetics and pharmacology research to lower blood lipid levels.

Corporate Structure

Verve employs between 201 and 500 professionals with expertise in cardiovascular medicine, genetics, gene editing, delivery technologies, and drug development. The company is led by co-founder and CEO Sekar Kathiresan, M.D., and operates from its Boston campus. Verve’s proprietary GalNAc-lipid nanoparticle (GalNAc-LNP) delivery platform is designed to target liver cells via the low-density lipoprotein receptor (LDLR) or asialoglycoprotein receptor (ASGPR).

Developments and News

On April 14, 2025, Verve announced initial data from its open-label Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease. A single intravenous infusion resulted in a mean LDL-C reduction of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort. No treatment-related serious adverse events or clinically significant laboratory changes were reported among the 14 participants.

On June 17, 2025, Verve entered into an agreement to be acquired by Eli Lilly and Company. This acquisition aims to utilize Lilly’s global research, clinical, regulatory, and commercial capabilities to expedite the development of Verve’s gene editing pipeline, which includes programs targeting ANGPTL3 and LPA.

Financial and Strategic Analysis

As of June 17, 2025, Verve’s stock price was $11.05, representing a 76.24% increase from the previous close, with a trading volume of 4,142,792 shares. Key financial metrics as of this date include:

• Market capitalization: $569.18 million
• Enterprise value: $140.74 million
• Price/Sales (ttm): 8.81
• Price/Book (mrq): 1.15
• Revenue (ttm): $59.61 million
• Net income (ttm): –$181.01 million
• Total cash (mrq): $497.08 million
• Total debt/Equity (mrq): 14.5%
• Levered free cash flow (ttm): –$64.11 million

Verve's operating losses reflect significant investment in research and development. With a cash balance nearing $500 million, the company possesses the financial resources to support ongoing trials and initial Phase 2 dosing, bolstered by Lilly’s resources post-acquisition.

Market Position and Industry Context

Atherosclerotic cardiovascular disease is recognized as the leading cause of death globally, with real-world adherence to lipid-lowering therapies often being inadequate. Verve's single-course gene editing approach seeks to achieve sustainable reductions in disease-driving lipids, shifting treatment from ongoing management to a single intervention. This positions Verve within the larger genetic medicines sector, competing alongside other gene therapy and editing innovators to redefine cardiovascular care.

TL;DR

On April 14, 2025, Verve’s Heart-2 Phase 1b trial of VERVE-102 demonstrated LDL-C reductions of up to 69% with no serious adverse events. On June 17, 2025, Verve agree to be acquired by Eli Lilly, intending to leverage Lilly’s expertise to advance Phase 2 studies of its gene editing programs targeting PCSK9, ANGPTL3, and LPA.